Katsuhito Nagai

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7541738/publications.pdf

Version: 2024-02-01

31	352	1040056	839539
papers	citations	9 h-index	18 g-index

31	31	31	535
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Doxorubicin alters the disposition of phenytoin by reducing its metabolic elimination and binding affinity to serum albumin in rats. Journal of Pharmacy and Pharmacology, 2022, 74, 200-207.	2.4	0
2	Effects of concurrent and staggered dosing of semi-solid enteral nutrients on pharmacokinetic behavior of antiepileptic drugs after oral administration in rats. PLoS ONE, 2021, 16, e0259400.	2.5	2
3	Differences in Transport Characteristics and Cytotoxicity of Epirubicin and Doxorubicin in HepG2 and A549 Cells. Anticancer Research, 2021, 41, 6105-6112.	1.1	3
4	Pharmacokinetic interference of doxorubicin with tolbutamide due to reduced metabolic clearance with increased serum unbound fraction in rats. Biopharmaceutics and Drug Disposition, 2019, 40, 225-233.	1.9	1
5	Enhanced anti-cancer activity by menthol in HepG2 cells exposed to paclitaxel and vincristine: possible involvement of CYP3A4 downregulation. Drug Metabolism and Personalized Therapy, 2019, 34, .	0.6	9
6	Conflicting alterations in hepatic expression of CYP3A and enzyme kinetics in rats exposed to 5-fluorouracil: relevance to pharmacokinetics of midazolam. Xenobiotica, 2019, 49, 1470-1477.	1.1	4
7	Effects of semi-solidification of enteral nutrients on the pharmacokinetic behavior of orally administered carbamazepine in rats. International Journal of Medical Sciences, 2019, 16, 1283-1286.	2.5	3
8	Alterations in Pharmacokinetics of Orally Administered Carbamazepine in Rats Treated with Sodium alginate: Possible Interaction between Therapeutic Drugs and Semi-solid Enteral Nutrients. Drug Research, 2019, 69, 168-172.	1.7	5
9	Prevention of Doxorubicin-Induced Renal Toxicity by Theanine in Rats. Pharmacology, 2018, 101, 219-224.	2.2	27
10	InÂvitro and inÂvivo effects of selected fibers on the pharmacokinetics of orally administered carbamazepine: Possible interaction between therapeutic drugs and semisolid enteral nutrients. Nutrition, 2018, 46, 44-47.	2.4	7
11	Altered tolbutamide pharmacokinetics by a decrease in hepatic expression of CYP2C6/11 in rats pretreated with 5-fluorouracil. Xenobiotica, 2018, 48, 53-59.	1.1	7
12	Compatibility of Intravenous Fat Emulsion with Antibiotics for Secondary Piggyback Infusion. Annals of Nutrition and Metabolism, 2018, 73, 227-233.	1.9	8
13	Bactericidal effects of deep ultraviolet light-emitting diode for solutions during intravenous infusion. International Journal of Medical Sciences, 2018, 15, 101-107.	2.5	6
14	Pharmacokinetics and metabolic elimination of tolbutamide in female rats: Comparison with male rats. Biopharmaceutics and Drug Disposition, 2018, 39, 321-327.	1.9	8
15	Water Soluble Vitamins Enhance the Growth of Microorganisms in Peripheral Parenteral Nutrition Solutions. International Journal of Medical Sciences, 2017, 14, 1213-1219.	2.5	4
16	Protective effects of taurine on doxorubicin-induced acute hepatotoxicity through suppression of oxidative stress and apoptotic responses. Anti-Cancer Drugs, 2016, 27, 17-23.	1.4	50
17	Survey on Usage of Adrenaline Auto-injection, Current Situation and Role of School Pharmacists in Education. Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences), 2016, 42, 31-39.	0.1	0
18	Theanine prevents doxorubicin-induced acute hepatotoxicity by reducing intrinsic apoptotic response. Food and Chemical Toxicology, 2015, 78, 147-152.	3.6	43

#	Article	IF	Citations
19	Decreased elimination clearance of midazolam by doxorubicin through reductions in the metabolic activity of hepatic CYP3A in rats. Xenobiotica, 2015, 45, 874-880.	1.1	5
20	Change in pharmacokinetic behavior of intravenously administered midazolam due to increased CYP3A2 expression in rats treated with menthol. Biopharmaceutics and Drug Disposition, 2015, 36, 174-182.	1.9	3
21	Effect of fluoxetine and pergolide on expression of nucleoside transporters and nucleicâ€related enzymes in mouse brain. Fundamental and Clinical Pharmacology, 2014, 28, 217-220.	1.9	5
22	Protection of theanine against doxorubicin-induced acute cardiac toxicity. Biomedicine and Preventive Nutrition, 2013, 3, 197-199.	0.9	6
23	Mouse Equilibrative Nucleoside Transporter 2 (mENT2) Transports Nucleosides and Purine Nucleobases Differing from Human and Rat ENT2. Biological and Pharmaceutical Bulletin, 2007, 30, 979-981.	1.4	9
24	Anticancer nucleobase analogues 6-mercaptopurine and 6-thioguanine are novel substrates for equilibrative nucleoside transporter 2. International Journal of Pharmaceutics, 2007, 333, 56-61.	5.2	34
25	Cytidine is a novel substrate for wild-type concentrative nucleoside transporter 2. Biochemical and Biophysical Research Communications, 2006, 347, 439-443.	2.1	10
26	Novel Na+-independent and adenine-specific transport system for adenine in primary cultured rat cortical neurons. Neuroscience Letters, 2006, 407, 244-248.	2.1	8
27	Contribution of an unidentified sodium-dependent nucleoside transport system to the uptake and cytotoxicity of anthracycline in mouse M5076 ovarian sarcoma cells. Biochemical Pharmacology, 2006, 71, 565-573.	4.4	9
28	Uptake of the anthracycline pirarubicin into mouse M5076 ovarian sarcoma cells via a sodium-dependent nucleoside transport system. Cancer Chemotherapy and Pharmacology, 2005, 55, 222-230.	2.3	8
29	Transport mechanisms for adenosine and uridine in primary-cultured rat cortical neurons and astrocytes. Biochemical and Biophysical Research Communications, 2005, 334, 1343-1350.	2.1	44
30	Pirarubicin is taken up by a uridine-transportable sodium-dependent concentrative nucleoside transporter in Ehrlich ascites carcinoma cells. Cancer Chemotherapy and Pharmacology, 2003, 51, 512-518.	2.3	12
31	Relationships between the in vitro cytotoxicity and transport characteristics of pirarubicin and doxorubicin in M5076 ovarian sarcoma cells, and comparison with those in Ehrlich ascites carcinoma cells. Cancer Chemotherapy and Pharmacology, 2002, 49, 244-250.	2.3	12